Welcome to our dedicated page for Fortress Biotech news (Ticker: FBIO), a resource for investors and traders seeking the latest updates and insights on Fortress Biotech stock.
Fortress Biotech, Inc. operates a biopharmaceutical business built around acquiring and advancing pharmaceutical and biotechnology assets. Company updates commonly cover product revenue, equity holdings, dividend and royalty income, FDA decisions, subsidiary transactions and clinical or regulatory progress across its portfolio.
Recurring news also includes Journey Medical dermatology products, Cyprium Therapeutics and ZYCUBO® for Menkes disease, priority review voucher monetization and corporate financial results. Fortress reports material developments involving approved prescription products, portfolio-company ownership, royalties, capital resources and business-development activity.
Journey Medical (Nasdaq: DERM) announced that Co-Founder, President and CEO Claude Maraoui will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on May 20, 2026. The virtual session is scheduled for 5:00 p.m. ET, with registration via the A.G.P. conference link.
Fortress Biotech (Nasdaq: FBIO) announced that Chairman, President and CEO Lindsay A. Rosenwald, M.D., will join a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on Wednesday, May 20, 2026, starting at 12:20 p.m. ET. Conference registration is available via A.G.P.’s online registration link.
Fortress Biotech (Nasdaq: FBIO) reported first quarter 2026 net income attributable to common stockholders of $108.4 million, or $3.44 basic and $2.82 diluted EPS, versus a prior-year loss. Consolidated revenue was $16.0 million, mainly from Journey Medical.
Cash and cash equivalents rose to $255.8 million, helped by Cyprium’s $205 million sale of a Priority Review Voucher, while Oaktree loan principal fell to $15.0 million. The FDA approved ZYCUBO for Menkes disease, creating new royalty and milestone opportunities alongside UNLOXCYT and Emrosi.
Journey Medical (Nasdaq: DERM) reported first quarter 2026 revenue of $16.0 million, up 21% year-over-year. Emrosi® revenue rose to $6.3 million. Gross margin was 61.0%, including a $1.3 million non-recurring non-cash inventory write-down.
Net loss narrowed to $2.2 million, while Adjusted EBITDA turned positive at $0.6 million. Cash and equivalents increased to $27.2 million. Emrosi® prescriptions reached 29,968, and a new GPO contract expands access to about 85% of U.S. commercial lives.
Journey Medical (Nasdaq: DERM) will release first quarter 2026 financial results after U.S. markets close on Wednesday, May 13, 2026.
Management will host a conference call and audio webcast on May 13, 2026 at 4:30 p.m. ET. Domestic dial-in is 1-866-777-2509; international dial-in is 1-412-317-5413. Registration is available at the provided URL and a replay will be available for ~30 days.
Fortress Biotech (Nasdaq: FBIO) announced that Lindsay A. Rosenwald, M.D., Chairman, President and CEO, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026 at 12:30pm ET.
According to Fortress Biotech, the session is virtual and registration is available via the conference website.
Journey Medical (Nasdaq: DERM) expanded payer access for Emrosi™, increasing commercial lives reached from approximately 100 million to over 150 million as of April 1, 2026.
Approximately 85% of U.S. commercial lives now have access after contracting with a third major GPO. The company expects expanded access to support prescription growth and improved brand profitability as formulary adoption progresses through 2026.
Fortress Biotech (Nasdaq: FBIO) reported 2025 results and material portfolio events. Key items: FDA approval of ZYCUBO® for Menkes disease, sale of a Rare Pediatric Disease PRV for $205 million by subsidiary Cyprium, and the May 2025 Checkpoint acquisition by Sun Pharma that generated ~$355 million upfront consideration to the seller group and a long‑term royalty stream.
Consolidated 2025 net revenue was $63.3M, R&D was $11.9M, SG&A was $96.4M, and net loss attributable to common stockholders was $1.9M (‑$0.07 per share).
Fortress Biotech (Nasdaq: FBIO) and majority-owned subsidiary Cyprium Therapeutics closed the sale of Cyprium’s Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million on March 30, 2026. Fortress expects to receive over $100 million of the proceeds, improving liquidity for business development.
The PRV was issued after FDA approval of ZYCUBO on January 12, 2026. Cyprium remains eligible for tiered royalties on ZYCUBO sales and up to approximately $128 million in aggregate sales milestones from Sentynl. Cyprium must pay 20% of PRV proceeds to the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Journey Medical (Nasdaq: DERM) reported full-year 2025 results and corporate highlights on March 25, 2026. Total revenues were $61.9 million, up 10% from $56.1 million in 2024, driven by the commercial launch of Emrosi™ (net revenues $14.7 million; ~53,000 prescriptions).
Gross margin improved to 66.2%, Adjusted EBITDA was $2.9 million, cash was approximately $24.1 million, and working capital was $29.4 million. Net loss narrowed to $11.4 million (−$0.47/share).